Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study comparing mosunetuzumab plus lenalidomide to rituximab plus lenalidomide in relapsed or refractory follicular lymphoma, including a US extension o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsed or Refractory Follicular Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING